Log in

NYSE:NVTAInVitae Stock Price, Forecast & News

$33.11
+1.04 (+3.24 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$31.09
Now: $33.11
$33.45
50-Day Range
$17.06
MA: $29.13
$34.41
52-Week Range
$7.41
Now: $33.11
$35.33
Volume2.85 million shs
Average Volume3.18 million shs
Market Capitalization$4.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.16
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Read More
InVitae logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone415-374-7782

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$216.82 million
Book Value$3.93 per share

Profitability

Net Income$-241,960,000.00
Net Margins-127.42%

Miscellaneous

Employees1,300
Market Cap$4.14 billion
Next Earnings DateN/A
OptionableOptionable
$33.11
+1.04 (+3.24 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InVitae (NYSE:NVTA) Frequently Asked Questions

How has InVitae's stock been impacted by COVID-19 (Coronavirus)?

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 108.9% and is now trading at $33.11.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of InVitae?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae
.

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) announced its quarterly earnings results on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.16. The medical research company had revenue of $46.20 million for the quarter, compared to analyst estimates of $39.63 million. InVitae had a negative net margin of 127.42% and a negative return on equity of 69.95%. The company's revenue for the quarter was down 14.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.54) earnings per share.
View InVitae's earnings history
.

What price target have analysts set for NVTA?

5 brokerages have issued 1-year target prices for InVitae's shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate InVitae's share price to reach $32.80 in the next twelve months. This suggests that the stock has a possible downside of 0.9%.
View analysts' price targets for InVitae
.

Has InVitae been receiving favorable news coverage?

News stories about NVTA stock have been trending neutral on Wednesday, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. InVitae earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about InVitae
.

Who are some of InVitae's key competitors?

What other stocks do shareholders of InVitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

Who are InVitae's key executives?

InVitae's management team includes the following people:
  • Dr. Randal W. Scott, Exec. Chairman (Age 61)
  • Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
  • Mr. Lee Bendekgey, Sec. & COO (Age 61)
  • Ms. Laura D'Angelo, Head of Investor Relations

When did InVitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are InVitae's major shareholders?

InVitae's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Profit Investment Management LLC (0.13%), Moody Aldrich Partners LLC (0.12%), Mackay Shields LLC (0.08%), First Trust Advisors LP (0.04%) and Sigma Planning Corp (0.03%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae
.

Which major investors are selling InVitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Profit Investment Management LLC, OTA Financial Group L.P., Dupont Capital Management Corp, Focused Wealth Management Inc, and CWM LLC. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae
.

Which major investors are buying InVitae stock?

NVTA stock was bought by a variety of institutional investors in the last quarter, including Mackay Shields LLC, First Trust Advisors LP, K.J. Harrison & Partners Inc, Moody Aldrich Partners LLC, Cresset Asset Management LLC, Coastal Investment Advisors Inc., ProShare Advisors LLC, and Strs Ohio.
View insider buying and selling activity for InVitae
.

How do I buy shares of InVitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InVitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $33.11.

How big of a company is InVitae?

InVitae has a market capitalization of $4.14 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

What is InVitae's official website?

The official website for InVitae is www.invitae.com.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.